相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
Tushar Garimella et al.
ANTIVIRAL THERAPY (2015)
Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
Gregory J. Dore et al.
GASTROENTEROLOGY (2015)
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson et al.
HEPATOLOGY (2015)
Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C
Yoshihide Ueda et al.
HEPATOLOGY RESEARCH (2015)
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
Donald Jensen et al.
JOURNAL OF HEPATOLOGY (2015)
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection
Tarek Hassanein et al.
JOURNAL OF HEPATOLOGY (2015)
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
D. L. Wyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides
Vineela Chukkapalli et al.
VIROLOGY (2015)
Ledipasvir-Sofosbuvir: Interferon-/ Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection
Michael A. Smith et al.
ANNALS OF PHARMACOTHERAPY (2015)
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Christophe Hezode et al.
GUT (2015)
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
K. Kosaka et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection
Lucia Rose et al.
ANNALS OF PHARMACOTHERAPY (2014)
Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity
Chunfu Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
Marc Bifano et al.
ANTIVIRAL THERAPY (2014)
A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection
Fumitaka Suzuki et al.
ANTIVIRAL THERAPY (2014)
Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1
Namiki Izumi et al.
ANTIVIRAL THERAPY (2014)
The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus
Timothy Eley et al.
CLINICAL DRUG INVESTIGATION (2014)
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
Adriano M. Pellicelli et al.
DIGESTIVE AND LIVER DISEASE (2014)
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gregory T. Everson et al.
GASTROENTEROLOGY (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2014)
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Makonen Belema et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition
James H. Nettles et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns et al.
LANCET (2014)
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark S. Sulkowski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone
Tushar Garimella et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Screening for Hepatitis C Virus Infection in Adults: US Preventive Services Task Force Recommendation Statement
Virginia A. Moyer
ANNALS OF INTERNAL MEDICINE (2013)
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir
Marc Bifano et al.
ANTIVIRAL THERAPY (2013)
THE EFFECT OF COADMINISTRATION OF THE PROTON-PUMP INHIBITOR OMEPRAZOLE ON THE PHARMACOKINETICS OF DACLATASVIR IN HEALTHY SUBJECTS
M. Bifano et al.
JOURNAL OF HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
Stanislas Pol et al.
LANCET INFECTIOUS DISEASES (2012)
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
Anna S. Lok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Multiple Ascending Dose Study of BMS-790052, a Nonstructural Protein 5A Replication Complex Inhibitor, in Patients Infected with Hepatitis C Virus Genotype 1
Richard E. Nettles et al.
HEPATOLOGY (2011)
Genotypic and Phenotypic Analysis of Variants Resistant to Hepatitis C Virus Nonstructural Protein 5A Replication Complex Inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell et al.
HEPATOLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
Choongho Lee et al.
VIROLOGY (2011)
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
Robert A. Fridell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
分享论文
